Gushukang capsule combined with anti-osteoporosis drugs promote postoperative healing of elderly fragile hip fractures

doi:10.3877/ cma.j.issn.1674-134X.2025.01.004

Abstract

Abstract:

Objective

To understand the effect of Gushukang capsule combined with antiosteoporosis drugs on clinical healing after internal fixation of fragile hip fracture in the elderly.

Methods

A total of 60 patients diagnosed with unilateral femoral intertrochanteric fracture combined with senile osteoporosis, and concurrent with internal fixation surgery in Foshan Jianxiang Orthopedics Hospital were collected from January 2022 to June 2023.Patients with other site fractures, other bone diseases, secondary osteoporosis, pathological fracture and other diseases were excluded.According to the random number, patients were divided into western medicine group (30 cases) and Gushukang capsule group (30 cases).The control group received denosumab + menatetrenone capsules + vitamin D + calcium for six months.The Gushukang capsule group received Gushukang capsule for six months on the basis of the same medicine strategy as the control group.Bone metabolism indices, fracture healing rate, visual analogue scale(VAS) and Harris hip score(HHS)were collected from both groups and statistically analyzed by t test and chi square test.

Results

The decrease in β-isomerized C-terminal telopeptide of type I collagen (β -CTX) was significant in the Gushukang capsule group than in the western medicine group at six months after treatment (t=2.04, P<0.05).The fracture healing rate in the Gushukang capsule group at three months after treatment was significantly higher than that in the western medicine group (χ²=4.32, P<0.05).The VAS score in the Gushukang capsule group at six months after treatment was significantly lower than that in the western medicine group (t=2.55, P<0.05).

Conclusion

For elderly patients after internal fixation of hip fragility fracture, Gushukang capsule combined with antiosteoporosis drug can relieve pain symptoms, improve bone metabolism, and promote clinical healing.

Key words: Traditional Chinese medicine, Osteoporosis, Hip fracture, Fracture healing

Jiaying Liu, Kangyan Liu, Jiangsheng Liang, Yuanliang Yang, Jia Su. Gushukang capsule combined with anti-osteoporosis drugs promote postoperative healing of elderly fragile hip fractures[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2025, 19(01): 21-26.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/ cma.j.issn.1674-134X.2025.01.004

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2025/V19/I01/21

Figures/Tables 4

Table 1 Comparison of general data of follow-up cases

组别Groups	例数Number of cases	性别（男/女）Gender (male/female)	年龄［岁，（ $\overset{ˉ}{x}$ ±s）］Age (year)	Evans分型（例）Evans classification
组别Groups	例数Number of cases	性别（男/女）Gender (male/female)	年龄［岁，（ $\overset{ˉ}{x}$ ±s）］Age (year)	Ⅱ型	Ⅲ型	Ⅳ型
对照组Control group	30	6/24	77. 0±6. 6	9	11	10
骨疏康组Gushukang group	30	9/21	76. 4±5. 9	10	8	12
统计值Statistical values		χ ²=0. 80	t=0. 43		χ ²=0. 71
P值		>0. 05	>0. 05		>0. 05
组别Groups	例数Number of cases	合并症（例） Complications				病程［d，（ $\overset{ˉ}{x}$ ±s）］Disease duration
组别Groups	例数Number of cases	高血压Hypertension	糖尿病Diabetes	冠心病Coronary heart disease	其它Other	病程［d，（ $\overset{ˉ}{x}$ ±s）］Disease duration
对照组Control group	30	11	8	9	2	4. 8±2. 5
骨疏康组Gushukang group	30	6	10	8	6	4. 4±2. 3
统计值Statistical values			χ ²=3. 75			t=0. 65
P值			>0. 05			>0. 05

Table 1 Comparison of general data of follow-up cases

组别Groups	例数Number of cases	性别（男/女）Gender (male/female)	年龄［岁，（ $\overset{ˉ}{x}$ ±s）］Age (year)	Evans分型（例）Evans classification
组别Groups	例数Number of cases	性别（男/女）Gender (male/female)	年龄［岁，（ $\overset{ˉ}{x}$ ±s）］Age (year)	Ⅱ型	Ⅲ型	Ⅳ型
对照组Control group	30	6/24	77. 0±6. 6	9	11	10
骨疏康组Gushukang group	30	9/21	76. 4±5. 9	10	8	12
统计值Statistical values		χ ²=0. 80	t=0. 43		χ ²=0. 71
P值		>0. 05	>0. 05		>0. 05
组别Groups	例数Number of cases	合并症（例） Complications				病程［d，（ $\overset{ˉ}{x}$ ±s）］Disease duration
组别Groups	例数Number of cases	高血压Hypertension	糖尿病Diabetes	冠心病Coronary heart disease	其它Other	病程［d，（ $\overset{ˉ}{x}$ ±s）］Disease duration
对照组Control group	30	11	8	9	2	4. 8±2. 5
骨疏康组Gushukang group	30	6	10	8	6	4. 4±2. 3
统计值Statistical values			χ ²=3. 75			t=0. 65
P值			>0. 05			>0. 05

Table 2 Comparison of bone metabolic indicators before and after treatment between the two groups

组别Groups	例数Number of cases	P1NP		β-CTXⅠ
组别Groups	例数Number of cases	治疗前Before treatment	治疗后6个月Six months after treatment	治疗前Before treatment	治疗后6个月Six months after treatment
对照组Control group	30	42. 99±6. 87	35. 24±19. 46	0. 83±0. 29	0. 26±0. 25^*
骨疏康组Gushukang group	30	42. 99±8. 41	28. 20±5. 00^*	0. 81±0. 28	0. 15±0. 12^*
t 值		＜0. 0001	1. 83	0. 22	2. 04
P值		>0. 05	>0. 05	>0. 05	0. 04
组别Groups	例数Number of cases	BGP		2,5(OH)Vith
组别Groups	例数Number of cases	治疗前Before treatment	治疗后6个月Six months after treatment	治疗前Before treatment	治疗后6个月Six months after treatment
对照组Control group	30	20. 90±5. 34	18. 16±7. 83	13. 43±6. 23	20. 23±5. 51^*
骨疏康组Gushukang group	30	21. 07±6. 93	15. 08±6. 86^*	13. 69±4. 10	22. 60±5. 48^*
t 值		-0. 10	1. 41	-0. 18	-1. 61
P值		>0. 05	>0. 05	>0. 05	>0. 05

Table 3 Comparison of healing rates between the two groups

组别Groups	例数Numberof cases	治疗3个月Three monthsafter treatment)	治疗6个月Six monthsafter treatment
对照组Control group	30	22（73. 3）	28（93. 3）
骨疏康组Gushukang group	30	28（93. 3）	30（100. 0）
χ ² 值		4. 32	-
P值		0. 04	0. 49^*

Table 4 VAS and HHS scores before and after treatment of the two groups

组别Groups	例数Number of cases	VAS评分		HHS评分
组别Groups	例数Number of cases	治疗前Before treatment	治疗后6个月Six months after treatment	治疗前Before treatment	治疗后6个月Six months after treatment
对照组Control group	30	4. 6±1. 0	2. 0±1. 2^*	39. 1±4. 5	81. 9±8. 2^*
骨疏康组Gushukang group	30	4. 7±1. 3	1. 2±1. 0^*	39. 3±5. 4	86. 1±7. 5^*
t 值		-0. 32	2. 55	-0. 15	-1. 77
P值		>0. 05	0. 02	>0. 05	>0. 05

References 21

［1］	中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南（ 2022 ）［J］.中华骨质疏松和骨矿盐疾病杂志, 2022, 15（ 6 ）: 573-611.
［2］	Dent E, Daly RM, Hoogendijk EO, et al.Exercise to prevent and manage frailty and fragility fractures［J］.Curr Osteoporos Rep,2023, 21（ 2 ）: 205-215.
［3］	吴斗, 刘强.骨质疏松性骨折手术治疗策略［J］.中国骨质疏松杂志, 2019, 25（ 5 ）: 581-584.
［4］	邱贵兴, 裴福兴, 胡侦明, 等.中国骨质疏松性骨折诊疗指南（全文）（骨质疏松性骨折诊断及治疗原则）［J/CD］.中华关节外科杂志（电子版）, 2015, 9（ 6 ）: 795-798.
［5］	朱俊.补肾健骨汤用于老年骨质疏松性髋部骨折术后的临床效果［J］.临床医学, 2018, 38（ 6 ）: 114-117.
［6］	陈孝平, 汪建平, 赵继宗.外科学［M］.9版.北京: 人民卫生出版社, 2018: 618-619.
［7］	Oh YK, Moon NH, Shin WC.Management of osteoporosis medication after osteoporotic fracture［J］.Hip Pelvis, 2022, 34（ 4 ）: 191-202.
［8］	赵成毅, 李青, 梁道臣, 等.椎体成形术后应用唑来膦酸联合维生素K2治疗老年性椎体压缩骨折［J/OL］.中华关节外科杂志（电子版）, 2018, 12（ 3 ）: 433-437.
［9］	申浩, 魏戌, 谢雁鸣, 等.绝经后骨质疏松症骨折危险因素及中医症状相关性研究［J］.中国中西医结合杂志, 2017, 37（ 1 ）:50-56.
［10］	周晓洁, 姚辛敏, 周妍妍.淫羊藿的药理作用研究进展［J］.中医药学报, 2022, 50（ 11 ）: 112-115.
［11］	中华医学会骨质疏松和骨矿盐疾病分会, 中华医学会骨科学分会骨质疏松学组.骨质疏松性骨折患者抗骨质疏松治疗与管理专家共识［J］.中华骨质疏松和骨矿盐疾病杂志, 2015, 8（ 3 ）:189-195.
［12］	胡妮娜, 张晓娟.黄芪的化学成分及药理作用研究进展［J］.中医药信息, 2021, 38（ 1 ）: 76-82.
［13］	陈磊, 陆茵, 郑仕中.丹参药理活性成分的整合效应［J］.中草药,2009, 40（ 3 ）: 476-479.
［14］	蔡伟明, 李延平.黄瓜籽多肽的抗骨质疏松作用［J］.中国医院药学杂志, 2011, 31（ 16 ）: 1333-1335.
［15］	郭军, 于水英, 王钜忠.骨疏康胶囊对腰椎压缩性骨折患者骨折愈合及椎体功能的影响［J］.中国药物与临床, 2021, 21（ 14 ）:2514-2516.
［16］	陈勇.骨疏康胶囊治疗绝经后骨质疏松性转子间骨折的临床效果分析［J］.中国骨质疏松杂志, 2019, 25（ 11 ）: 1571-1575.
［17］	陈昌博.骨疏康胶囊联合骨化三醇和阿仑膦酸钠治疗骨质疏松的临床疗效［J］.药品评价, 2017, 14（ 7 ）: 41-43, 63.
［18］	王茹, 李泉, 左庆瑶, 等.骨疏康胶囊联合唑来膦酸治疗老年骨质疏松症的临床疗效及对骨密度和骨代谢标志物的影响［J］.现代生物医学进展, 2023, 23（ 1 ）: 193-196, 186.
［19］	侍方, 李欣, 张蕊.骨疏康胶囊联合鲑鱼降钙素、戊酸雌二醇对绝经后骨质疏松患者的临床疗效［J］.中成药, 2020, 42（ 12 ）:3188-3192.
［20］	韩国瑞, 董卫兵, 明海武.骨疏康胶囊辅助治疗绝经后骨质疏松性股骨转子间骨折的临床效果分析［J］.中国合理用药探索,2021, 18（ 6 ）: 86-91.
［21］	龚健, 梁俊生, 张洪斌, 等.骨疏康胶囊联合股骨近端防旋髓内钉内固定治疗老年骨质疏松性股骨粗隆间骨折的临床效果［J］.中国医药, 2018, 13（ 7 ）: 1070-1074.

[1]	Yonghong Dai, Kuangyang Yang, Zhengjie Wu, Yanhui Zeng, Chunpeng Zhao, Junqiang Wang, Xinbao Wu. Early efficacy analysis of an intelligent minimally invasive reduction robot system for pelvic fractures [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(06): 795-799.
[2]	Gang Zheng, Weixin Cao, Qiang Fu, Jia Ou, Yu Cao, Caizhi Gu. Analysis on the effect of traditional Chinese medicine fumigation in the treatment of refractory wounds [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2025, 20(02): 117-121.
[3]	Rui Dai, Liang Zhang, Liuyang Chen, Yongbo Zhang, Pigen Wu, Hua Sun, Sheng Yang, Bo Meng. Research progress on the correlation between intestinal flora and intervertebral disc degeneration [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(06): 546-549.
[4]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of rectal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(01): 1-19.
[5]	Ying Chen, Yi Wang, Lu Wang, Desong Kong, Yang Zhang, Zhimin Fan. Advancements in the utilization of colorectal cancer organoids for investigating traditional Chinese medicine and its bioactive constituents [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(01): 47-52.
[6]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[7]	Tao Wang, Jing Liu, Yuwei Gao, Xinghua Wang, Xiuhong Hu, Hongrui Cui, Baozhen Xu, Hongjuan Yang. Research progress in the prevention and treatment of peritoneal dialysis-associated peritonitis with traditional Chinese medicine under the background of antibiotic resistance [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 340-344.
[8]	Xiaowei Wang, Hongmei Yang, Jie Gao, Huayong Zheng, Zhi Liu, Tiansheng Sun. The influence of type of anesthesia selection on the prognosis of hip fractures [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2025, 11(01): 39-45.
[9]	Mingming Tan, Shiqiang Zhan, Hongtao Hou, Xiangshuo Zeng. Clinical study on percutaneous minimally invasive pedicle screw fixation for patients with osteoporotic spinal compression fractures [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 349-354.
[10]	Fang Wang, Da Liu, Zhiwei Zuo, Jinping Sheng, Tingjin Chen, Rui Jiang. Meta-analysis of quantitative CT and dual energy X-ray absorptiometry in the diagnosis of osteoporo-sis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 363-371.
[11]	Shengxia He, Kaina Yang, Pu Li. Curative effect of Shenling Baizhu Powder combined with bifidobacterium triplet on functional constipation with spleen deficiency in children [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 73-77.
[12]	Peng Sheng, Lizhe1 Bai, Jing Zhang, Dan Li, Hong Cao. Galactooligosaccharides enhance intestinal barrier function and mitigate bone loss in ovariectomized mice [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(01): 48-57.
[13]	Xiaoming Bao, Xiaoping Zhang, Weidong Guo, Xin Dong, Kun Ren, Haien Zhao, Bo Liao. Efficacy of cortical bone trajectory versus pedicle screw fixation in treatment of patients with lumbar degenerative disease combined with osteoporosis [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(11): 980-985.
[14]	Jiana Shi, Linyan Qian, Kaiyue Ji, Jinwen Qi, Qing Hu, Jiabin Sun. Discussion of application of traditional Chinese medicine in atherosclerosis from the perspective of browning of white adipose tissue [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 853-858.
[15]	Yudong Sheng, Xiaoying Lyu, Ruojun Liao, Qi Zhang, Enshi Lu, Yanke Ai, Tianyi Zhao, Hongjiao Li. Construction of the “Individualized Thematic Evaluation” method for appropriate Chinese medicine techniques based on the training project of internal pediatric disease treatment with external techniques [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2025, 14(01): 41-44.

Please choose a citation manager

Content to export